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SUMMARY
1.  The aim of the present study was to characterize the source of plasma 
catecholamines induced by centrally administered glucagon-like peptide-1 (GLP-1), with 
regard to the brain prostanoids, in urethane-anesthetized rats. 
2.  GLP-1 and other compounds were administered intracerebroventricularly (i.c.v.), 
and blood samples were collected via a cannula inserted into the femoral artery. 
Catecholamines were extracted from plasma with activated alumina and were assayed 
electrochemically with high-performance liquid chromatography.
3.  GLP-1 (0.3, 1.0 and 3.0 nmol/animal) dose-dependently elevated plasma levels 
of noradrenaline and adrenaline, and GLP-1 (1.0 nmol)-induced response was reduced by 
exendin (5-39) (a selective GLP-1 receptor antagonist) in a dose-dependent manner (5 
and 10 nmol/animal). The GLP-1-induced elevation of both catecholamines was 
abolished by indomethacin (an inhibitor of cyclooxygenase ) (1.2 µmol/animal), while 
baicalein (a lipoxygenases inhibitor) (1.2 µmol/animal) had no effect.
4.  Furegrelate (an inhibitor of thromboxane A2 synthase) (1.8 µmol/animal) and (+) 
S-145 (a thromboxane A2 receptor antagonist) (625 nmol/animal) attenuated the 
GLP-1-induced elevation of plasma adrenaline, but these reagents had no effect on the 
elevation of plasma noradrenaline. The GLP-1-induced elevation of plasma adrenaline 
was abolished by acute bilateral adrenalectomy, but the procedure had no effect on the 
elevation of plasma noradrenaline.
5.  These results suggest that centrally administered GLP-1 induces the secretion of 
adrenaline from the adrenal medulla by brain thromboxane A2-mediated mechanisms, 
while the peptide evokes the release of noradrenaline from sympathetic nerves by brain 
prostanoid other than thromboxane A2-mediated mechanisms in rats. 
Key words:  cyclooxygenase,  glucagon-like peptide-1,  plasma catecholamine, 
sympatho-adrenomedullary system,  thromboxane A2.
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INTRODUCTION
Glucagon-like peptide-1 (GLP-1) was reported originally to be a peptide hormone 
released from the enteroendocrine L cells in the intestine to stimulate insulin secretion 
from the pancreas.1-3 GLP-1 is also a brain neuropeptide synthesized in the caudal regions 
of the nucleus of the solitary tract.4,5 Although the sites of GLP-1 synthesis in the brain 
are quite limited, GLP-1-immunoreactive nerve fibers and GLP-1 receptors are
widespread throughout the brain.6 It has been shown that intravenous and 
intracerebroventricular administration of GLP-1 receptor agonists increases blood 
pressure and heart rate and induces c-Fos-like immunoreactivity in autonomic regulatory 
neurons in the brain.7-9 These observations suggest a role for GLP-1 in the regulation of 
several autonomic responses in the brain.10 However, the central mechanisms underlying 
these actions of GLP-1 remain largely undefined. 
Previously, we reported that intracerebroventricular pretreatment with indomethacin, 
an inhibitor of cyclooxygenase, effectively reduced the increase of plasma noradrenaline 
and adrenaline induced by intracerebroventricularly (i.c.v.)-administered 
corticotrophin-releasing factor (CRF),11 arginine-vasopressin,12 and bombesin.13,14 These 
results suggest the involvement of brain prostanoids in the central activation of the 
sympatho-adrenomedullary outflow in rats. In the present study, therefore, we 
investigated the mechanisms involved in i.c.v.-administered GLP-1-induced elevation of 
plasma catecholamines with regard to the brain prostanoids in urethane-anesthetized rats.
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METHODS
Experimental procedures
Male Wistar rats weighing approximately 350 g were maintained in an air-conditioned 
room at 22-24ºC under a constant day-night rhythm for more than 2 weeks and given food 
(laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. With the 
rats under urethane anesthesia (1.0 g/kg, i.p.), the femoral vein was cannulated for 
infusion of saline (1.2 mL/h), and the femoral artery was cannulated for collecting blood 
samples, as described previously.15 For some animals, acute bilateral adrenalectomy 
(plus hydrocortisone 5 mg/kg, i.m.) or a sham operation (plus 200 µL saline/animal, 
i.m.)16 was carried out just before the experiments through bilateral dorsal incisions using 
an aseptic surgical technique.
Next, the animal was placed in a stereotaxic apparatus, as described previously.14 A 
hole was drilled in the skull for intracerebroventricular administration of test substances 
through a stainless-steel cannula (0.3 mm outer diameter). The stereotaxic coordinates of 
the tip of the cannula were as follows (in mm): AP, -0.8; L, 1.5; V; 4.0 (AP, anterior from 
the bregma; L, lateral from the midline; V, below the surface of the brain), according to 
the rat brain atlas of Paxinos and Watson.17 Three hours were allowed to elapse before the 
application of GLP-1 or other reagents.
GLP-1 and other reagents (except for baicalein) were dissolved in sterile saline and 
injected slowly into the right cerebral ventricle in a volume of 5 µL with a 10-µL 
Hamilton syringe. In the case of baicalein, the reagent was dissolved in N, N-dimethyl 
formamide (DMF) and injected slowly into the right cerebral ventricle in a volume of 2.5 
µL with a 10-µL Hamilton syringe. Exendin (5-39) (a GLP-1 receptor antagonist) and (+) 
S-145 (a thromboxane A2 receptor antagonist) were administered i.c.v. 15 min before 
GLP-1 administration. Water-soluble indomethacin-Na (a cyclooxygenase inhibitor), 
baicalein (a lipoxygenase inhibitor) and furegrelate (a thromboxane A2 synthase 
inhibitor) were administered i.c.v. 30 min before GLP-1 administration. 
All experiments were conducted in compliance with the guiding principles for the 
care and use of laboratory animals approved by Kochi University.
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Measurement of plasma catecholamines
Blood samples (250 µL) were collected through an arterial catheter and preserved on ice 
during the experiments. Plasma was prepared immediately after the final sampling. 
Catecholamines in the plasma were extracted by the method of Anton and Sayre,18 with a 
slight modification, and were assayed electrochemically with high-performance liquid 
chromatography (HPLC).15 Briefly, after centrifugation, plasma (100 µL) was transferred 
to a sample tube containing 30 mg of activated alumina, 1 ng of 
3,4-dihydroxybenzylamine as an internal standard, and 3 mL of 0.5 M Tris buffer (pH 
8.6) containing 0.1 M disodium EDTA. The tube was shaken for 10 min, and the alumina 
was washed three times with 4 mL of ice-cold, double-deionized water. Then, the 
catecholamines adsorbed onto the alumina were eluted with 300 µL of 4% acetic acid 
containing 0.1 mM disodium EDTA. 
A pump (EP-300: Eicom, Kyoto, Japan), a sample injector (Model-231XL; Gilson, 
Villiers-le-Bel, France), and an electrochemical detector (ECD-300: Eicom) equipped 
with a graphite electrode were used with HPLC. Analytical conditions were as follows: 
detector +450 mV potential against an Ag/AgCl reference electrode; column, Eicompack 
CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M NaH2PO4-Na2HPO4 buffer (pH 
6.0) containing 50 mg/L disodium EDTA, 750 mg/L 1-octane sulfate sodium (Nacalai 
Tesque, Kyoto, Japan) and 15% methanol, at a flow rate of 0.18 mL/min. The amount of 
catecholamines in each sample was calculated using the peak height ratio relative to that 
of 3,4-dihydroxybenzylamine. This assay could determine 0.5 pg of noradrenaline and 
adrenaline accurately.
Treatment of data and statistics
Results are expressed as the mean±S.E.M. of the net change above the respective basal 
values. The data were analyzed by repeated-measure analysis of variance (ANOVA), 
followed by post-hoc analysis with the Bonferroni method for comparing a control to all 
other means (Figs. 1, 2 and 4B). When only two means were compared, the data were 
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analyzed with an unpaired Student’s t-test (Figs. 3, 4A and 5). P values less than 0.05 
were taken to indicate statistical significance.
Compounds
GLP-1 (7-36 amide) and exendin (5-39) were purchased from Peptide Institute (Osaka, 
Japan). Baicalein and furegrelate sodium were obtained from Biomol Research Labs 
(Plymouth Meeting, PA, USA). Water-soluble indomethacin sodium trihydrate and (+) 
S-145 were kind gifts from Merck (Rahway, NJ, USA) and Shionogi Pharmaceutical Co. 
Ltd. (Osaka, Japan), respectively. All other reagents were purchased from Nacalai 
Tesque (Kyoto, Japan).
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RESULTS
Effect of GLP-1 on the plasma levels of catecholamines
Administration of vehicle (5 µL of saline/animal) and blood sampling five times over a 
60-min period had no effect on the basal plasma levels of either noradrenaline or 
adrenaline (Fig. 1). 
GLP-1 dose-dependently elevated plasma levels of noradrenaline and adrenaline 
(Fig. 1). The noradrenaline response to GLP-1 (0.3 and 1.0 nmol/animal) reached a 
maximum at 20-30 min after administration of the peptide, and then gradually declined to 
near basal levels, while the response to GLP-1 (3.0 nmol/animal) reached a maximum at 
20 min after administration of the peptide, and elevated levels were maintained 
throughout the experiments. The plasma adrenaline response to GLP-1 (0.3, 1.0 and 3.0 
nmol/animal) reached a maximum at 20 min after administration of the peptide, and then 
gradually declined to near basal levels (Fig. 1). 
Effect of exendin (5-39) on the GLP-1-induced elevation of plasma catecholamines
Pretreatment with exendin (5-39) (a GLP-1 receptor antagonist) (10 nmol/animal) had no 
effect on the basal plasma levels of noradrenaline and adrenaline (Fig. 2).
Pretreatment with vehicle (5 µL of saline/animal) slightly, but not significantly, 
potentiated the effect of GLP-1 (1.0 nmol/animal) on the plasma level of noradrenaline 
(Fig. 2). The GLP-1-induced elevation of plasma catecholamines was attenuated by 
pretreatment with exendin (5-39) in a dose-dependent manner (5 and 10 nmol/animal) 
(Fig. 2). 
Effects of indomethacin and baicalein on the GLP-1-induced elevation of plasma 
catecholamines
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Pretreatment with indomethacin (a cyclooxygenase inhibitor) (1.2 µmol [500 µg]/animal) 
or baicalein (a lipoxygenase inhibitor) (1.2 µmol [400 µg]/animal) had no effect on the 
basal plasma levels of noradrenaline and adrenaline, respectively (Fig. 3, A and B). 
Pretreatment with indomethacin (1.2 µmol/animal) effectively reduced the elevation 
of both catecholamines induced by GLP-1 (1.0 nmol/animal) (Fig. 3A). In contrast, 
pretreatment with baicalein (1.2 µmol/animal) slightly, but not significantly, elevated the 
GLP-1-induced responses (Fig. 3B).
Effects of furegrelate and (+) S-145 on the GLP-1-induced elevation of plasma 
catecholamines
Pretreatment with furegrelate (a thromboxane A2 synthase inhibitor) (1.8 µmol [500 
µg]/animal) had no effect on the basal plasma levels of noradrenaline and adrenaline (Fig. 
4A). Pretreatment with furegrelate significantly reduced the elevation of adrenaline 
induced by GLP-1 (1.0 nmol/animal), but the reagent had no effect on the elevation of 
noradrenaline induced by this peptide (Fig. 4A). 
According to our previous report,14 we used (+) S-145 (a thromboxane A2 receptor 
antagonist) at doses of 250 and 625 nmol/animal in the present experiment (Fig. 4B). 
Pretreatment with this reagent (625 nmol/animal) had no effect on the basal plasma levels 
of noradrenaline and adrenaline. Pretreatment with this reagent effectively attenuated the 
GLP-1 (1.0 nmol/animal)-induced elevation of adrenaline in a dose-dependent manner 
(250 and 625 nmol/animal), while it slightly, but not significantly, reduced the elevation 
of noradrenaline induced by this peptide (Fig. 4B).
Effect of bilateral adrenalectomy on the GLP-1-induced elevation of plasma 
catecholamines 
The basal plasma levels of noradrenaline and adrenaline were reduced slightly by sham 
operation. The basal plasma level of noradrenaline was reduced slightly, but not 
significantly, by bilateral adrenalectomy, while the basal plasma level of adrenaline was 
reduced significantly by the procedure (Fig. 5).
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The GLP-1 (1.0 nmol/animal)-induced elevation of plasma adrenaline was 
abolished by bilateral adrenalectomy, while the procedure had no effect on the 
peptide-induced elevation of plasma noradrenaline (Fig. 5).
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DISCUSSION
In the present experiment, centrally administered GLP-1 effectively elevated plasma 
levels of catecholamines (adrenaline > noradrenaline), and these elevations were 
suppressed dose-dependently by exendin (5-39), a GLP-1 receptor antagonist.19  Several 
lines of evidence indicate that centrally administered GLP-1 induces a dose-dependent 
increase in blood pressure and heart rate.9,20,21 Furthermore, it has been shown that an 
activation of the GLP-1 receptors in the rat brain induces c-Fos expression in neurons 
involved in autonomic control sites, including the hypothalamic paraventricular nucleus 
and medullary neurons providing output to sympathetic preganglionic neurons.9 Taken 
together, it would be reasonable to assume that centrally administered GLP-1 elevates 
plasma catecholamines via an activation of brain GLP-1 receptors in rats.
Previously, we reported that the brain cyclooxygenase is involved in centrally 
administered CRF-, arginine-vasopressin-, and bombesin-induced elevations of plasma 
noradrenaline and adrenaline using indomethacin in rats.11,12,13 The elevation of plasma 
noradrenaline induced by centrally administered interleukin-1ß was also attenuated by 
central pretreatment with indomethacin.22 Since indomethacin is a potent inhibitor of the 
prostaglandin-forming cyclooxygenase,23 active products of cyclooxygenase seem to be 
involved in the elevations of plasma catecholamines induced by these peptides in rats. 
However, it remains possible that active products of the brain lipoxygenases are involved 
in the elevations of plasma catecholamines induced by these peptides. 
In the next experiment, therefore, we examined the effects of centrally administered 
indomethacin and baicalein, a lipoxygenase inhibitor,24 on the GLP-1-induced elevation 
of plasma catecholamines. These reagents were directly administered into the lateral 
ventricle of the rat brain. The elevation of plasma catecholamines induced by GLP-1 was 
abolished by central pretreatment with indomethacin (1.2 µmol/animal). In contrast, the 
same dose of baicalein had no attenuating effect on the GLP-1-induced elevation of 
plasma catecholamines. Collectively, it would be reasonable to assume that the active 
products of cyclooxygenase seem to be involved in the GLP-1-induced elevation of 
plasma catecholamines in rats.
We have already reported that furegrelate, a selective thromboxane A2 synthase 
inhibitor,25 abolished the elevation of plasma adrenaline induced by centrally 
administered CRF, arginine-vasopressin, or bombesin.11,12,14 Furthermore, injection of a 
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thromboxane A2 mimetic into the hypothalamic paraventricular nucleus predominantly
elevates plasma adrenaline.26 These results suggest the involvement of brain 
thromboxane A2 in the elevation of plasma adrenaline induced by these peptides. Then, 
we examined the effect of furegrelate on the GLP-1-induced elevation of plasma 
catecholamines. The GLP-1-induced elevation of plasma adrenaline was reduced by 
centrally administered furegrelate, while the reagent was without effect on the 
GLP-1-induced elevation of plasma noradrenaline. Furthermore, (+) S-145, a 
thromboxane A2 receptor antagonist,14  also attenuated the GLP-1-induced elevation of 
plasma adrenaline, but not that of noradrenaline. Based on these results, it would be 
reasonable to assume that the brain thromboxane A2 is involved in the GLP-1-induced 
elevation of plasma adrenaline.
In general, plasma noradrenaline reflects the activity of the sympathetic nervous 
system, while plasma adrenaline reflects the activity of the adrenomedullary system. 
Recently, we demonstrated that centrally administered arginine-vasopressin, bombesin 
and histamine elicit adrenal secretion of both noradrenaline and adrenaline by brain 
thromboxane A2-mediated mechamisms, while centrally administered CRF elicits 
sympathetic noradrenaline release and adrenal adrenaline secretion by brain 
prostaglandin E2- and thromboxane A2-mediated mechanisms, respectively, in rats.14-16
Furthermore, it has been reported that noradrenaline-containing cells and 
adrenaline-containing cells in the adrenal medulla are innervated separately by 
preganglionic neurons in the spinal cord.27 More recently, using c-Fos expression, we 
demonstrated that adrenaline- and noradrenaline-containing cells in the adrenal medulla 
and celiac sympathetic ganglia are differentially controlled by brain thromboxane A2 and 
prostanoids other than thromboxane A2 (probably prostaglandin E2), respectively, in 
rats.28 In the last experiment, we performed acute bilateral adrenalectomy to determine 
the origin of plasma catecholamines induced by centrally administered GLP-1. Bilateral 
adrenalectomy abolished the centrally administered GLP-1-induced elevation of plasma 
adrenaline, while the procedure had no effect on the elevation of plasma noradrenaline. 
These results suggest that centrally administered GLP-1 evokes noradrenaline release 
from sympathetic nerves and adrenaline secretion from the adrenal gland in rats. 
GLP-1-containing nerve terminals densely innervate neurons in the hypothalamic 
paraventricular nucleus,29 which has been recognized as a regulatory center of the 
sympatho-adrenomedullary system.30 These observations further support the present 
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results that central GLP-1-containing neurons regulate central 
sympatho-adrenomedullary outflow in rats.
In summary, we demonstrated here that centrally administered GLP-1 evokes 
adrenal adrenaline secretion by brain thromboxane A2-mediated mechanisms and 
sympathetic noradrenaline release by mechanisms involving prostaglandins other than 
thromboxane A2 (probably prostaglandin E2) in rats.
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FIGURE LEGENDS
Fig. 1  Effect of GLP-1 on plasma catecholamine levels. Arrow indicates the 
administration of GLP-1 (0.3, 1.0 and 3.0 nmol/animal, i.c.v.) or vehicle (5 µL 
saline/animal, i.c.v.). , vehicle (n = 4); , 0.3 nmol (n = 9); , 1.0 nmol (n = 10); , 
3.0 nmol (n = 5). *Significantly different (P < 0.05) from vehicle (5 µL saline)-treated 
control with Bonferoni method. Each point represents the mean±S.E.M. The actual 
values for noradrenaline and adrenaline at 0 min were 400±46 and 322±45 pg/mL (n =
28), respectively. 
Fig. 2  Effect of exendin (5-39) (a GLP-1 receptor antagonist) on the GLP-1-induced 
elevation of plasma catecholamines. Exendin (5-39) (5 and 10 nmol/animal, i.c.v.) or 
vehicle-1 (5 µL saline/animal, i.c.v.) was administered 15 min before GLP-1 (1.0 
nmol/animal, i.c.v.) or vehicle-2 (5 µL saline/animal, i.c.v.). , vehicle-1 plus vehicle-2 
(n = 4); , exendin (5-39) (10 nmol/animal) plus vehicle-2 (n = 4); , vehicle-1 plus 
GLP-1 (n = 16); , exendin (5-39) (5 nmol/animal) plus GLP-1 (n = 5); , exendin 
(5-39) (10 nmol/animal) plus GLP-1 (n = 6). *Significantly different (P < 0.05) from 
vehicle-1 (5 µL saline)- and GLP-1-treated group with Bonferoni method. Other 
conditions were the same as those in Fig. 1. The actual values for noradrenaline and 
adrenaline at 0 min were 376±56 and 263±56 pg/mL in the vehicle-1 (5 µL 
saline)-pretreated group (n = 20), 580±68 and 376±83 pg/mL in the exendin (5-39) (5 
nmol)-pretreated group (n = 5), 204±23 and 180±54 pg/mL in the exendin (5-39) (10 
nmol)-pretreated group (n = 10), respectively.
Fig. 3  Effects of indomethacin (a cyclooxygenase inhibitor) and baicalein (a 
lipoxygenase inhibitor) on the GLP-1-induced elevation of plasma catecholamines. (A) 
Indomethacin (1.2 µmol/animal, i.c.v.) or vehicle-1 (5 µL saline/animal, i.c.v.) was 
administered 30 min before GLP-1 (1.0 nmol/animal, i.c.v.) or vehicle-2 (5 µL 
saline/animal, i.c.v.). , vehicle-1 plus vehicle-2 (n = 4); , indomethacin plus 
vehicle-2 (n = 4); , vehicle-1 plus GLP-1 (n = 12); , indomethacin plus GLP-1 (n = 7). 
(B) Baicalein (1.2 µmol/animal, i.c.v.) or vehicle-1 (2.5 µL DMF/animal, i.c.v.) was 
administered 30 min before GLP-1 (1.0 nmol/animal, i.c.v.) or vehicle-2 (5 µL 
saline/animal, i.c.v.). , vehicle-1 plus vehicle-2 (n = 3), , baicalein plus vehicle-2 (n
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= 5); , vehicle-1 plus GLP-1 (n = 6); , baicalein plus GLP-1 (n = 5). *Significantly 
different (P < 0.05) from vehicle-1 (5 µL saline/2.5 µL DMF)- and GLP-1-treated group 
with Student’s t-test in (A) and (B), respectively. Other conditions were the same as those 
in Figs. 1 and 2. The actual values for noradrenaline and adrenaline at 0 min were 430±64
and 224±21 pg/mL in the vehicle-1 (5 µL saline)-pretreated group (n = 16), 457±82 and 
500±100 pg/mL in the indomethacin-pretreated group (n = 11) in (A); 354±47 and 
221±65 pg/mL in the vehicle-1 (2.5 µL DMF)-pretreated group (n = 9), 314±42 and 
341±77 pg/mL in the baicalein-pretreated group (n = 10) in (B), respectively.
Fig. 4  Effects of furegrelate (a thromboxane A2 synthase inhibitor) and (+) S-145 (a 
thromboxane A2 receptor antagonist) on the GLP-1-induced elevation of plasma 
catecholamines. (A) Furegrelate (1.8 µmol/animal, i.c.v.) or vehicle-1 (5 µL 
saline/animal, i.c.v.) was administered 30 min before GLP-1 (1.0 nmol/animal, i.c.v.) or 
vehicle-2 (5 µL saline/animal, i.c.v.). , vehicle-1 plus vehicle-2 (n = 4) (cited from Fig. 
3A); , furegrelate plus vehicle-2 (n = 6); , vehicle-1 plus GLP-1 (n = 12) (cited from 
Fig. 3A); , furegrelate plus GLP-1 (n = 6). (B) (+) S-145 (250 and 625 nmol/animal, 
i.c.v.) or vehicle-1 (5 µL saline/animal, i.c.v.) was administered 15 min before GLP-1 
(1.0 nmol/animal, i.c.v.) or vehicle-2 (5 µL saline/animal, i.c.v.). , vehicle-1 plus 
vehicle-2 (n = 4) (cited from Fig. 2); , (+) S-145 (625 nmol/animal, i.c.v.) plus 
vehicle-2 (n = 3); , vehicle-1 plus GLP-1 (n = 16) (cited from Fig. 2); , (+) S-145 
(250 nmol) plus GLP-1 (n = 4); , (+) S-145 (625 nmol) plus GLP-1 (n=6). 
*Significantly different (P < 0.05) from vehicle-1 (5 µL saline)- and GLP-1-treated group 
with Student’s t-test in (A) and Bonferoni method in (B), respectively. Other conditions 
were the same as those in Figs. 1-3. The actual values for noradrenaline and adrenaline at 
0 min were 430±64 and 224±21 pg/mL in the vehicle-1 (5 µL saline)-pretreated group (n
= 16), 425±43 and 319±40 pg/mL in the furegrelate-pretreated group (n = 12) in (A); 
376±56 and 263±56 pg/mL in the vehicle-1 (5 µL saline)-pretreated group (n = 20), 
143±11 and 155±58 pg/mL in the (+) S-145 (250 nmol)-pretreated group (n = 4), 251±55 
and 126±30 pg/mL in the (+) S-145 (625 nmol)-pretreated group (n = 9) in (B), 
respectively.
Fig. 5  Effect of acute bilateral adrenalectomy on the GLP-1-induced elevation of 
catecholamines. Hydrocortisone (5 mg/kg) or saline (200 µL/animal) was administered 
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intramuscularly in the adrenalectomized group () or sham-operated group (), 
respectively. Arrow indicates the administration of GLP-1 (1.0 nmol/animal, i.c.v.). 
*Significantly different (P < 0.05) from sham-operated group with Student’s t-test. Other 
conditions were the same as those in Figs. 1-4. The actual values for noradrenaline and 
adrenaline at 0 min were 281±81 and 143±36 pg/mL in the sham-operated group (n = 5) 
and 99±17 and 52±6 pg/mL in the bilateral adrenalectomized group (n = 5), respectively. 
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